All Articles

Best Practices in Lung Cancer Navigation

Identification of new actionable targets and driver mutations have revolutionized the treatment of NSCLC

Educating Patients About the Need to Wait for Biomarker Test Results

By Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T); Cathy Simmons, RN, BSN, ONN-CG(T); Lauren Welch, MSN, NP-C, AOCNP

Best Practices in Lung Cancer Navigation

Waiting for biomarker test results ensures the best outcomes in NSCLC.

Explaining the Treatment Trajectory in NSCLC

By Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T); Cathy Simmons, RN, BSN, ONN-CG(T); Lauren Welch, MSN, NP-C, AOCNP

Best Practices in GU Navigation

Describing the road map of the cancer care journey in NSCLC.

The Multidisciplinary Care Approach to Cancer Care Management

By Megan Price, MSN, APRN, FNP-C; Virginia Seery, CRNP, MSN; Laura Wood, RN, MSN, OCN

American Cancer Society Cancer Action Network Releases Recommendations to Increase Cancer Biomarker Testing

There are an ever-growing number of treatment options that are contributing to more successful outcomes and higher survival rates for cancer patients. The number of care providers that cancer patients need during their journey is also expanding. Please join Laura Wood, RN, MSN, OCN, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, as they discuss the role of the multidisciplinary care team approach to deliver the best possible treatment for cancer patients.

Sotorasib Demonstrates Efficacy in CodeBreaK 100 Phase 2 Study Results

The American Cancer Society Cancer Action Network has published data that demonstrate there are multiple barriers to biomarker testing access and released recommendations that address these barriers.

Results of an International Study Identify Barriers to Molecular Testing in NSCLC

Sotorasib has shown promising antitumor activity in phase 2 of a clinical trial of patients with heavily treated advanced NSCLC.

Adagrasib Shows Promising Results in Pretreated KRAS-Mutant NSCLC

Recently released survey responses identified multiple barriers to, and dissatisfaction with, the current state of molecular testing in lung cancer.